Argenx reported a Phase 3 win for Vyvgart Hytrulo in autoimmune myositis, but the company said the drug missed the mark in a key patient subgroup. The subcutaneous therapy is intended for a rare autoimmune disease family, and the company framed the overall readout as meeting its late-stage objective. Subgroup misses can complicate label scope and post-approval utilization even when the primary endpoint is positive. For clinicians and payers, the practical question becomes which patient characteristics track with the strongest response and whether subsequent analyses drive refinement. Investors will likely parse subgroup outcomes alongside safety and durability as Argenx prepares for next steps in the development and potential regulatory discussions.